pro medicus

OUR SUPPORT. YOUR SUCCESS.

AGM November 2025

Chairman's Address

Pro Medicus Ltd
AGM
24 November 2025

CHAIRMAN'S REPORT

Overview

The Company has enjoyed another extremely successful year both from an operational and financial point of view.

The success of the Company in the markets that we serve continues to be due to the quality of our leading technology and quality of the management team; the passion, enthusiasm and dedication of all of our staff; and the robustness of our business model. The Company continued to deliver the highest level of service to our clients and their patients.

Your company is fortunate to have a group of highly skilled professionals led by Dr. Sam Hupert and the management team; the majority of our staff has been with the company for many years and the core management team for well over a decade.

As a consequence the company has continued to deliver long-term, profitable and sustainable financial results by delivering on the milestones in accordance with the company's strategic plan.

The group continues to invest in our best of breed suite of innovative products - to maintain market leadership, which we believe is fundamental to your company's success. In addition, we look to further add to our product suite by acquisition or licensing arrangement.

We also continue to invest in our management and staff, which is growing in line with our strategic objectives. (Dr. Hupert will provide further commentary in relation to the Company's personnel in his presentation).

New Contract Wins & Renewals

During the FY25 year the company announced 7 new contract wins in North America including our largest contract to date, Trinity Health, which commenced implementation in late October 2025, along with many others implemented during the year.

Since 1 July 2025 the Company has announced six new contracts, five in North America (including those announced today) and one in Germany, as well as one client renewal at increased per transaction fees and with additional products.

An increasing number of new opportunities continue to present themselves and as a result our pipeline remains strong.

Financial Results

FY2025 was another record year for the company with revenue increasing by 31.9% to $213 million and net profit after tax increasing by 39.2% to $115.2 million.
The Company continued to be cash flow positive with retained cash and liquid investments increasing from $155.4 million to $210.7 million, after a $A7.9m buyback of shares in March/April and paying increased dividends.
The Board anticipates FY26 will be another strong year.

The budget for the current financial year has been determined anticipating continuing strong profitable growth, from both existing and new clients.

I am pleased to advise that results to date are ahead of budget on both a constant currency basis and an Australian dollar basis, despite some volatility in currency markets during the period.

We are entering the second half with strong momentum, driven by the successful completion of Trinity Phase 1 and the University of Iowa implementations in late October, both of which will contribute a full six months of revenue in the second half . In addition, we have several major contracts scheduled to go live early in the second half. We therefore anticipate the second half bias will be greater this financial year than previous years.

Surplus cash and M&A

As I indicated earlier, our cash and other financial instruments have continued to grow during the year. These funds are maintained to allow the company to continue to invest in the development of our product suite (including AI), to meet our dividend obligations and to take advantage of opportunities that might arise.

In July 25 the company invested $10m in ASX listed company 4D Medical Ltd. This is in the form of a loan with very attractive terms and conditions. The Board is also continually investigating potential M&A opportunities which meet our criteria and this process is ongoing.

Dividend Policy

The Board was pleased to increase dividend payments for the 2025 financial year to 55 cents per share fully franked. This represents an increase of 37% over the previous year and a payout ratio of approximately 50%. The dividends were funded from the company's internally generated cash flow.

The Board anticipates that future dividends will continue to be fully franked. The Board will continue to determine an appropriate level of dividends having regard to the profitability of the business, its need for ongoing investment and the necessity to retain sufficient funds to pursue other growth opportunities.

pro medicus
OUR SUPPORT. YOUR SUCCESS.

Strategic Planning

The 2026 financial year is the final year of our current three year strategic plan and the Board and senior management are confident that the company will achieve all of the strategic goals which were set three years ago.
However, we do not intend to rest on our laurels!
Last month the Board and senior management met to discuss the next three years of the company's development.

The meeting noted our current market position and the opportunities for further growth. The meeting determined another set of ambitious targets for FY27 to FY29 and agreed on strategies to reach the ultimate goal.

Closing

In closing, on your behalf, I would again like to thank all of our dedicated staff in Australia, North America and Europe for their contribution to the company during what has been another very successful year. I would also like to thank my fellow directors who have also worked tirelessly and diligently to ensure that the company continues to grow and prosper.

pro medicus

OUR SUPPORT. YOUR SUCCESS.

AGM November 2025

CEO Presentation

PRO MEDICUS (ASX:PME)

Healthcare IT company specializing in Enterprise Imaging and Radiology Information System (RIS) software.

Leading edge products, growing global presence.

Pro Medicus (ASX:PME)

VISAGE RIS

promedicus.net

VISAGE 7
Enterprise Imaging Platform

Results FY 2025

$213.0M
Revenue
up 31.9%

$115.2M
Profit after tax
up 39.2%

$157.7M
Underlying EBIT
up 40.5%

74.0%
Underlying EBIT
margins

$210.7M
Cash &
investments
up 35.5%

Company is
debt free

Strong
balance sheet

$0.30
Final dividend FF
up 37.5%

FY 2025 Revenue Split



Highlights FY 2025

Ann & Robert H. Lurie Children's Hospital of Chicago

$5M/7 years
New Contract

JULY 2024

Trinity Health

$330M/10 years
New Contract

NOVEMBER 2024

duly HEALTH AND CARE

$30M/7 years
New Contract

DECEMBER 2024

UK HealthCare

$33M/9 years
New Contract

JANUARY 2025

BayCare

$53M/7 years
New Contract

FEBRUARY 2025

Continues to grow
STRONGLY
CURRENT PIPELINE

Highlights FY 2025

Continues to grow
STRONGLY
CURRENT PIPELINE

LucidHealth — Clearly, the future of radiology.
$40M/7 years
New Contract
MARCH 2025

IOWA HEALTH CARE
$20M/5 years
New Contract
APRIL 2025

NYU Langone Health
$24M/5 years
Upgrade
APRIL 2025

DukeHealth
$14M/5 years
Upgrade
JUNE 2025

Mercyhealth — A passion for making lives better.
$98M/8 years
Renewal Contract
OCTOBER 2024


$32M/5 years
Renewal Contract
OCTOBER 2024

RSNA®
NOVEMBER/DECEMBER 2024


7 IMPLEMENTATIONS FY2025

FY 2025 – Results

- Record year
- Seven new contracts totaling AUD $520M (at minimums)
- Two large contract renewals – worth AUD $130M
- Upgrades for additional products – additional AUD $39M
- Completed seven cloud-based implementations
- Signed research collaboration agreement with UCSF
- RSNA 2024 the busiest to date
- Significant progress with other “ologies” and AI
- Forms strong base for growth in FY26 and beyond



Highlights - FY26 YTD

uchealth
$170M/10 years
New Contract &
Cardio9logy
JULY 2025

Franciscan Missionaries of Our Lady HEALTH SYSTEM
$20M/5 years
Renewal & Archive
Upgrade
JULY 2025

UNIVERSITÄT HEIDELBERG ZUKUNFT SEIT 1386
$10M/5 years
New Contract
OCTOBER 2025

(ARM)
$44M/5 years
New Contract
NOVEMBER 2025

x 3
$29M TCV
3 New Contracts
NOVEMBER 2025

Continues to grow
STRONGLY
CURRENT
PIPELINE

FY26 Progress - YTD

- Performance ahead of growth budget
- On track to deliver on or above 3-year strategic plan (FY24 to 26)
- Sales in 1st five months have combined minimum TCV of $273M
- Successfully implemented phase 1 of Trinity rollout – largest single “big bang” in industry (October)
- Successfully completed U Iowa implementation (November)
- Bookings for RSNA 2025 very strong



FY26 Progress – 2nd Half

- 1st half building momentum for 2nd half
- Full 6 months of revenue Trinity Phase 1 and U Iowa
- U Kentucky go live scheduled for December 2025
- 3 large implementations scheduled for 1st 3 months of FY26 to contribute to 2nd half
- Existing Client volumes continue to grow well above industry average.
- Pipeline forecast to grow post RSNA 2025
- 2nd half bias expected to be greater than previous years



VISAGE RIS


Visage RIS - Dr R Simpson (rsna) visage2 (2) @ Visage General Hospital (ris.promed.com.au)
RECEPTION TECHNOLOGIST DOCTOR TRANSCRIPTIONIST SEARCH OFFICE CLAIMING SETUP
Recent Dr R Simpson
Appointments Requested Arrival Billing Banking
Region Northern Book Visage General Hospital Tue, 17-Oct-2017 AM PM Patient Procedure Cancelled Blocked Reset
Visage X-ray
Visage CT
Visage US Room 1
Visage US Room 2
Visage US Room 3
Visage Mammo
Blocked
SMITH, Mr John: C...
Lunch
Non Contrast
ADAMS, Mrs ROSE ...
TEST, Mr Roger: U...
Test 43.607...
Urgent
Edit Appointment
APPOINTMENT
Tue, 17-Oct-2017
10:30 AM - 11:00 AM
Mr John SMITH
FOLIO 10.645
ACCESSION 10.1270
Male 05-Oct-1977 (40y) H: (03) 1212-1211 Visage General Hospital Visage
450 Swan Stree... Dr Doogie Ho (03) 9800-1231 Appointment(s) Medium
SUMMARY
Patient SMITH, Mr John 10.645
Born: 05-Oct-1977 (40y)
Male
(03) 1212-1211
Address 450 Swan Street RICHMOND VIC 3121
View all details
Referrer Dr Doogie Howser 0000000Y
Practice
Address 23 Holywood lane ThePlace RICHMOND VIC 3121 Australia
Referral date 09-Oct-2017
Referral period 12
Accession 10.1270
Order Status Arrived (1/1)
Save Cancel

VISAGE RIS

I-MED Network Radiology
Comprehensive care. Uncompromising quality.

Healthcare Imaging Services
Affordable | Accessible | Imaging

- Long term (5 year) contracts with Lumus (Primary Healthcare) and I–MED, the 2 biggest radiology providers in AUS
- Upside via client organic and M&A growth
- Increased market interest – new opportunities
- PME undisputed market leader

Visage® 7

SPEED | FUNCTIONALITY | SCALABILITY

Massive Data Explosion

- High density Multi-slice CT - 10,000+ images
- HD Breast Tomosynthesis - 6 GB+
- Optoacoustic breast ultrasound - 10+ GB
- Total Body PET Scan - 10+ GB
- 7T MRI - much larger than 3T



Legacy Technology

"Compress & Send"



Solution

“Streaming Technology”

MODALITIES

RADIOLOGIST/CLINICIAN

In Review

2025/2026 Top Hospitals

(alphabetical order)

Out of the top-rated U.S. hospitals (11 out of 20) use Visage 7 for PACS.



Increasing Footprint in the IDN Space

- IDNs represent the largest segment of the market
- IDN clients across broad spread of opportunities from large multi-state to smaller regional
- Most recent IDN sales for more than one Visage product – many “full stack”.
- All recent IDN opportunities Cloud deployed
- BSW and Trinity (Phase 1) implementations redefine “time to go live”.
- Increasing network effect in this important market segment.

Trinity Health

- One of the top 10 IDNs in North America
- $330M (minimum), 10-year deal
- Full Stack – Viewer worklist and archive
- To be fully cloud deployed
- Phase 1 Implemented on time in October 2025
- Next four key regions to be phased in by June 2026
- One of the largest deals in radiology IT

Private Market

- Previously “dormant” due to increased M&A activity
- Duly Health $30M – 7 Year deal (Dec 2024)
- Lucid Health $40M - 7 Year deal (March 2025)
- ARM - $44M - 5 Year Deal (November 2025)
- Confirms Visage platform ideally suited to broad range market segments
- Growing network effect in private market space

University of Colorado Health

- $170M – 7-year deal, 2nd largest in company's history
- "Full Stack plus 1" - Includes Visage 7 Cardiology offering
- Highly respected hospital system based in Aurora Colorado
- University of Colorado Hospital - AMC Medical school and research center for Colorado University
- Hybrid AMC and IDN

Heidelberg University

- A$10M – 5-year deal
- Top German medical school and teaching hospital
- Affiliated German Cancer Research Institute largest cancer research centre in Europe
- Increases PME footprint in Germany/Europe

Fast Track Implementation

- All implementations on or ahead of schedule
- Fast track methodology continues to deliver
- Large scale projects completed in under 1/4 to 1/5 the time of industry norm
- Delivers huge savings for client
- Frees PME staff for other jobs
- Reduces barrier to change
- Highly optimized implementation model (onsite + remote)
- Massive differentiator for Visage offering

Visage – Proven ROI

Significant IT &
Infrastructure Savings

Unparalleled increase in
Radiologist Efficiency

Greater Clinical Accuracy



Improved Physician
Engagement

Delivers Superior
Value Proposition

Chair of the Commission on Economics
Gregory N. Nicola, MD, FACR

How Will We Solve Our Radiology Workforce Shortage?

As the U.S. population ages, government-funded residency programs are not keeping pace with an increasing need for more radiologists.

"There is a palpable shortage of radiologists in practices and academic departments across the United States, with more than **1,400** physician positions posted right now on the ACR job board."

Visage 7 Brings Relief – Burnout – the new epidemic?

- Acute worldwide shortage of radiologists
- Reduced intake of radiology residents – fears AI would take over
- Larger datasets – more images to look at
- Work life balance post COVID – work from home mandatory part of the mix
- Many groups struggling to handle current workload
- Groups starting to cut back on existing contracts

Clinical Outcomes – Moving the Needle



Growth Strategy

North American – TAM



- 670 Million exams performed per annum in the US
- Growing by ~ 2% to 3% per year
- Visage able to address 100% of TAM from a product perspective
- ~ 85% of TAM addressable from commercial perspective – “full stack”, Cloud etc
- Current market penetration is now >10% and growing
- Very large addressable runway

North American Pipeline



Pipeline Robust
In terms of quality and quantity of opportunities

Opportunities
Increased number of inbound RFPs

Network Effect
Further increased from recent high-profile wins in Tier 1academic, IDN and Private markets

Prospects
Progressing through various stages of the cycle

Visage 7 Open Archive

- Same highly scalable Visage 7 platform
- Interoperable – works in complex environments
- Enables choice of modular or single vendor solutions
- Visage 7 Open Archive integral part of “Full Stack” solution
- Pipeline - most opportunities include Visage 7 Open Archive
- Key component of Visage Cloud strategy
- Transaction based model with potential upside



Visage 7 Workflow

- Adds to Visage 7 Viewer and Open Archive modules
- Based on over 30 years experience in Workflow SW
- Allows PME to offer “full stack” solution
- Integral part of Visage CloudPACS SaaS solution
- Ability to interface with broad range of AI algorithms
- Sold in majority of new contracts
- Transaction based model with potential upside

Visage 7 CloudPACS

- Visage 7 – fully Cloud native
- Even faster than on-premise
- Full Visage 7 functionality
- Security and scale of the cloud
- Suitable for all size implementations

Visage 7 CloudPACS

- Pipeline opportunities mandating Cloud deployment
- Cloud vendor agnostic - large scale implementations in all three clouds - AWS, Azure and Google GCP
- Key competitors can only offer “hybrid” solutions - on premise with cloud backup
- Visage 7 CloudPACS - significant strategic advantage over competitors

Visage 7 One Viewer - All Modalities

- Single viewer for ALL images in the medical record (EMR)
- Radiology/Cardiology/Pathology
- Non-radiology– reflected light – hi-res photos & videos
- Same code base as Visage 7 platform
- Increases Visage value proposition
- Growth opportunities within existing contracts

Visage 7 | Cardiology

- Cloud-based Workflow and Imaging Solutions for Cardiology Imaging
- Same code base as Visage 7 platform
- Ultrafast, immediate access to massive Cardiology datasets
- Native Cardiology Imaging tools
- Advanced interoperability, - export measurements to Epic Cupid



Visage 7 | Digital Pathology

- Native support within the Visage 7 Enterprise Imaging Platform (WIP)
- Fully Cloud-based (Visage 7 | CloudPACS)
- Spatial computing support via Visage Ease VP for Apple Vision Pro (WIP)
- Validation of IHE Digital Pathology Profile at the 2025 IHE-Europe Connectathon

Visage 7 | Digital Pathology



Visage 7 | AI

- Breast cancer detection algorithm co-developed with NYU - commercialization pending FDA clearance
- Investment in Elucid for Cardiac CT AI
- Investment in 4DX – Lung AI
- Research collaboration agreement with UCSF, a top AMC
- Growing number of 3rd party AI integrations

AI Research Leadership

Malte Westerhoff, PhD

Global Chief Technology Officer

Detlev Stalling, PhD

Head of Development

MingDe Lin, PhD

Clinical Research Manager, North America

Solution

Visage® 7



Pro Medicus – 25 Years as a listed company

IPO – 10th October 2000

Pre IPO 1997 to 2000

Profile:

Pro Medicus ~ Leader in Medical Computer Systems

Anthony Hall and Sam Hupert

Profile is back, and this issue is bursting with news. Since our last edition there have been many exciting changes here at Pro Medicus: new premises, new logo, new people, new products ... all of which you can read about in this issue.

From the Desk

The last two years have seen enormous changes at Pro Medicus -- all exciting and positive.

As many of you are aware, we have moved to our new premises at 450 Swan Street in Richmond, pictured below. We are extremely proud of our new building, which was granted an award by the Australian Institute of Architects. Being purpose built, our new home provides us with a base for expansion and better caters for areas of specialisation such as research and development, technical/application support, client training and conferences.

Along with the additional space we also welcome several new members to the Pro Medicus team, all of whom are introduced on page 3. We have brought on board additional specialists in programming, support and training, logistics and sales/marketing. Their skills and experience complement our established competencies, and together we've been kept busy releasing a number of major updates. Version 3.01 of Pro Medicus includes new accounting facilities, while the recently-released Versions 3.02 and 3.03 are specifically designed to cater for 1 November accounting changes for diagnostic imaging billing.

In addition, we have also released a number of new products for all segments of the medical industry. These include:

- ▲ Pro Medicus Management Information System (MIS), the first interactive marketing tool that allows practices to dynamically view ad hoc requests by location or referrer in graphical/report form
- ▲ new versions of Sectra/Teleradiology
- ▲ an interface to Medical Director that offers clear and accurate script generation for both GPs and Specialists.

Hardware advancements have also been high on our agenda, with the early adoption of the latest generation of Intel processors, the 686.

So enjoy this issue of Profile, our first for 1997. We hope you had a happy festive season and look forward to sharing many future exciting developments with you.

Best wishes

Sam Hupert
Managing Director

Anthony Hall
Technical Director

Our new, award-winning office in Richmond

Profile:

Issue No 2 October 1999

Pro Medicus ~ Medical E-Commerce and Imaging

Anthony Hall and Sam Hupert

Welcome to a new issue of Profile, jam packed with information on Year 2000 compliance, release of Pro Medicus 2000 and the new Electronic Appointment System. We hope your year so far has been as busy and successful as ours.

From the Desk

Welcome to Profile. Those of you with an eye for detail will notice we've updated the photo on the cover - it's amazing what a difference 10 years makes!

The grey hairs and "laughter lines" are partly attributable to the fact that things have been hectic for us here at Pro Medicus, particularly with the chaos of the new millennium.

In addition to the development of new applications, much of our focus has been on ensuring our software and your systems are Year 2000 compliant.

By now, all of you will have received our Year 2000 White Paper, which includes a test diskette for checking your server's BIOS and operating system patches, and a "discovery sheet" for summarising the results and returning to us. If you have not as yet run the BIOS check and returned your sheet, please ensure you put aside some time in the next month to do so.

We are starting to roll out Pro Medicus 2000, and you will be receiving appropriate documentation in the coming weeks. This will be provided at no additional cost for those with an ongoing support contract.

As part of the upgrade, we will work with you to ensure that Year 2000 patches are applied to your entire suite of software. While Pro Medicus has been proactive in its approach to Year 2000, many issues are out of our hands. As the millennium draws closer, operating system developers and third-party software suppliers are refining their products. We will continue to ensure that we disseminate information to you as definitions come to hand.

Since our last newsletter we've also released one of our most exciting products, an Electronic Appointment System which has been specifically designed for use in medical practices. It was a long development cycle, as fundamentally, we needed to change the paradigm of a manual system. The breakthrough concept is that of a virtual book which can be used on an enterprise-wide basis.

Many of our clients have moved to a fully networked environment, and as a result are taking advantage of the benefits of a range of medical electronic commerce applications such as e-mail, electronic transmission of reports and group-wide knowledge bases. Our e-commerce solutions are detailed on page 3.

In this issue we also introduce the newest staff members to join our team of highly talented and customer-focussed professionals.

Finally, you will start reading in the press speculation on the impact of the GST on systems. Fear not, our R & D team is evaluating the impact on our software. We are staying abreast of key developments, and will take necessary steps to ensure your systems can cater for required changes.

As always, we hope you enjoy reading this issue of Profile. Best wishes,

Sam Hupert
Managing Director

Anthony Hall
Technical Director

25th Anniversary PME Pre IPO – March 2000



25th Anniversary PME IPO – 10th October 2000



Float hopes: Promedicus founders Anthony Hall and Dr Sam Hupert are listing their company. Picture: JOE ARMAO

Float just what doctor ordered

25th Anniversary PME IPO



Chairman Mel Ward, left, with CEO Sam Hupert and tech director Anthony Hall. Picture: JOE

Healthy premium for doctors' dotcom

SMALL CAPS

Robin Bromby

THERE must have been some audible sighs of relief at Pro Medicus's Melbourne headquarters last Tuesday after the first hours of trading in the company's newly listed shares.

With the Nasdaq sagging and local investors increasingly avoiding the dotcom sector, it was not the most propitious moment to list a company selling medical software and e-health services.

However, Pro Medicus shares listed at $1.41, a 23 per cent premium to their $1.15 issue price. Even at week's end and after a shocking Thursday night on the Nasdaq, investors were still ahead. Shares were trading on Friday at $1.25.

It probably helped that this was no Johnnie-come-lately with a vague idea of making heaps of cash from streaming data on the internet.

Its customers are doctors and laboratories, not teenagers who may or may not click on banner ads.

Indeed, Pro Medicus has been around since 1983 and 80 per cent of the stock is held by its two founders, Sam Hupert and Anthony Hall.

Dr Hupert, a former GP, was relieved the company did so well in what he called a 'share market hailstorm".

But everything was too far advanced to alter course when the market started to look brittle.

"These listing processes take place over a long time period and they're difficult to stop," he said.

Dr Hupert said there was no urgent financial necessity to raise the $23 million by floating off 20 per cent of the company. But it made it easier to offer staff a stake in the business, a... makes it possi... scrip-based acqu...

Dr Hupert a... puter system...

Momentum: Pro Medicus CEO Sam Hupert and technical director Anthony Hall

Picture: David Croslin...

Anthony Hall started Pro Medicus 17 years ago and now have 80 per cent of the diagnostic imaging market in Australia.

This enables radiologists to send results of X-rays and other tests directly into the computers of the referring ... cutting out dupli...

also a benefit to patients in that using computers to transmit pathology results meant systems could be programmed to look for unusual results and pick up errors.

Pro Medicus sells software packages that organise most of a doctor's surgery paperwork including appointments...

ensure its growth and succes... One is the ageing of th... population and the cons... quent demand for medic... services.

The other — directly relat... — is the need by government to control health costs as th... population gets older an... treatments become mor... ... and expensive.

Pro Medicus stags have a field day

SHARES in medical software supplier Pro Medicus traded at a pre-... price of $1.15 a share.

Managing director and co-founder Sam ...

information technology products and services to medical practitioners ...

Medicus had no current plans to raise capital but ...

Big demand for Promedicus float

Lachlan Johnston

E-health group Promedicus is expected to unveil the details of its $23 million float to the public this week, after being inundated in its offer to institutional investors.

The float, underwritten by J.B. Were & Son, is understood to be priced at $1.15 per share, giving the group a market capitalisation ...

The float is likely to focus market attention on the growing competition to provide Internet services to doctors.

Promedicus's corporate profile claims the company provides information technology "solutions to the medical profession". This includes practice management software applications, as well as networking ...

11/10/00

The Sydney Morning Herald

Pro Medicus lists at healthy premium

Medical software supplier Pro Medicus rocketed as high as 41 per cent above its float offer price when it listed on the Australian Stock Exchange yesterday.

The company, which plans to ...s software available over ...ernet, opened trading at ... before jumping as high as ... a 41 per cent premium to ...15 offer price.

capital, as well as to allow the establishment of an employee option plan.

Dr Hupert and Mr Hall will continue to hold 80 per cent of the company's shares.

The offer was keenly sought by institutional investors, despite the sell-down and the relatively high price to earnings multiple of 23 times on which the float had ...

25th Anniversary PME IPO

- October 2000 - Issued capital 100M shares @ $1.15
- Current shares on issue 104,495,170
- Increase of 4,495,170 (<5%) over 25 years
- All new shares issued as part of staff LTI
- Company has been self funding throughout
- Remains debt free to this day

Visage Ease VP for Apple Vision Pro



"Underpins our belief that our technology is 18 to 24 months ahead of competitors, if not more."

Visage Ease VP for Apple Vision Pro

Spotlight: Reimagining Radiology with Apple Vision Pro

Apple Michigan Avenue Mon, December 16:00 p.m. – 7:00 p.m. Apple Michigan Avenue

Discover how Apple Vision Pro is helping to pioneer what’s possible in radiology. Join Dr. Elias G. Kikano, Dr. Paul M. Murphy, and Dr. Andrew C. Gordon, along with Dr. Malte Westerhoff from Visage Imaging, as they share insights on how spatial computing is transforming medical imaging. They’ll also discuss personal experiences within their own healthcare facilities.



RSNA 2024


Visage is Ahead of the Curve.
DEL MEDICAL
CloudPACS Café
VISAGE IMAGING

RSNA 2024


VISAGE IMAGING
Visage is Ahead of the Curve.
NOVARAD
Neusoft Medical Systems

In Summary - FY25

- Most successful year in company's history
- Expanded product portfolio – "full stack" solution
- Proven implementation & support capability
- Cloud – huge strategic advantage over competitors
- Unparalleled value proposition both clinical and financial RoI
- North American footprint and pipeline continue to grow strongly
- 1st Cardiology site live – UC Health (Colorado) to follow in FY26
- Visage 7 Digital pathology (WIP)
- Visage well positioned to leverage AI as it becomes mainstream
- Increasing use cases for Visage Ease VP for Apple Vision Pro

In Summary - FY26 - YTD

- Off to a strong start
- Contracted Sales in 1st 5 months - minimum TCV of A$273M
- Phase 1 Trinity & U Iowa implementations successfully completed (Oct & Nov)
- Company set to deliver on 3-year growth plan (FY24 to FY26)
- Company ahead of budget YTD
- U Kentucky on track to go live December 2025
- Strong momentum going into 2nd half FY2026

Thank you.